Halozyme Wins in The Hague, Waits in Washington — and the Stock Already Knows

A record royalty quarter, a final Dutch judgment against Merck's Keytruda Qlex, and a second delivery engine that still needs a Phase 1 — all landing 6% below an all-time high

HALO · Earnings Call · 2026-11-05

The quarter arrives into a re-rated stock

Halozyme's third quarter was, on every operating line, the best in the company's history: total revenue of $493 million (+39% year over year), record royalties of $341 million (+44%), adjusted EBITDA of $336 million at a 68% margin, and a guidance raise that pushed the full-year revenue range to $1.86–1.925 billion with royalty revenue alone at $1.235–1.255 billion. The engine underneath is a royalty book that has finally diversified: Darzalex added $153.5 million (+20%), Vyvgart Hytrulo $88.1 million (+89%), Phesgo $34.3 million (+23%), and — the number that matters most for the next decade — the catch-all "other" line, which houses Ocrevus Zunovo, Opdivo Qvantig and Rybrevant Faspro, grew 92% to $65.1 million. Which is exactly why the tape deserves top billing. The reaction is not the story; the setup is. HALO is up 59.7% over the last 90 trading days in a single unbroken uptrend, printed an all-time closing high of $131.18 on 2026-10-29, and enters this print just 6.3% below it. Very little of what management said on Thursday was a surprise to the price. Latest filed revenue of $481M, +48% year over year confirms the trajectory; free cash flow (less stock comp) of $219M, up 155% shows how little capital intensity the model demands.

Europe won. America is still on appeal.

The genuinely new thing this quarter was a courtroom. On October 7, 2026 — after a full trial, not a preliminary skirmish — the Dutch court handed Halozyme a decisive victory on EP 622, its MDase patent covering modified hyaluronidase for large-volume subcutaneous delivery. The Dutch court finding went well beyond the usual: it held not only that Keytruda Qlex infringed, but that there was no reasonable likelihood the patent would be invalidated in other relevant European member states, and it barred Merck's European approval holder from manufacturing, offering, marketing, importing or stocking the product in eight countries — Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.

the Specialized Dutch Patent Court of The Hague rejected Merck's invalidity challenges against Halozyme's MDase patent EP622 and found Keytruda QLEGS to be infringing the patent. The Court also found that there was no reasonable likelihood that EP622 will be declared invalid in the other relevant European member states
Helen Torley, President and Chief Executive Officer · 2026-11-05

Read that against what management said in August, and the trajectory snaps into focus. Then, Europe was an ambition: “We are currently actively pursuing injunctions in approximately eight countries outside the U.S. with the goal of stopping the Merck infringing use of our MDASE technology. This includes the launch in countries as well as manufacturing, distribution and supply of Qlex for worldwide use.” — Helen Torley, President and CEO · 2026-08-06 Three months later, the eight countries are covered by a judgment and Halozyme has gone further, suing the Italian fill-finish contractor BSP Pharmaceuticals directly. Helen Torley was careful but pointed about what that implies for Merck's global supply: the prohibition “does impact those entities' ability to supply Qlex from BSP entity regardless of the ultimate destination of the product” — Helen Torley, President and Chief Executive Officer · 2026-11-05 — though she explicitly declined to comment on U.S. supply. That is where the story inverts. In the United States, Merck has won multiple adverse validity decisions on Halozyme's PGRs, and Halozyme's path runs through an appeal likely stretching to 2028. And there is no settlement thaw: “We haven't engaged in any conversations with Merck” — Helen Torley, President and Chief Executive Officer · 2026-11-05 — a notably flat answer against a keyword the model still scores as conversations with Merck. Investors are being asked to underwrite an asymmetric legal outcome: ~20% of global royalties secured in Europe and Germany by court order, and the far larger U.S. market held by conviction rather than judgment.

The second engine, quietly renamed

Beneath the legal noise, Halozyme is trying to prove the ENHANZE model is repeatable. The evidence this quarter: three existing partners expanded and nominated four new targets (argenx to eight exclusive targets, Incyte adding one, J&J adding another oncology target), and three ENHANZE-enabled programs entered Phase 1, taking the company to twelve in the clinic with a thirteenth planned by year-end — the enhanced programs in clinical development count management has been marching toward all year. The more speculative leg is the hyperconcentration technology stack. HyperCon now has five collaboration agreements covering more than 20 potential targets, with clinical supply for the first two partner products due in Q1 2027 ahead of first-half Phase 1 starts, and a scale-up process management describes as nearly through the hard part. But note the framing discipline: pressed on the $1 billion HyperCon royalty ambition, Torley gave the same construction she gave in August — “we were looking at an expectation of having 5 to 7 products that would be in the clinic by the mid- before the mid-2030s” — Helen Torley, President and Chief Executive Officer · 2026-11-05 — which is nearly verbatim what she said three months ago: “As we projected the $1 billion in the mid-2030s, we had assumed between five and seven launches by that time period.” — Helen Torley, President and CEO · 2026-08-06 Reassuring, but not new information. What is new is a name change. Surf Bio, the acquisition that dominated the keyword set in early 2026, is now AeroCon — and the Surf Bio keyword, which spiked hard last winter, has since fallen into the decliner list. That rebranding is a small tell: the earlier-stage asset is being repositioned as a platform sibling rather than a standalone thesis, with 2026 spend intact, deal signings expected in 2027 and clinical entry in the second half of 2028.

The question that will not retire

Every analyst on this call circled the same cliff: royalty step-downs on the big established products, led by Darzalex, whose base composition-of-matter patents run out around 2029. Management's answer is unchanged and correct — collaboration patents co-formulation IP that in many contracts extends the royalty term and, in some cases, preserves the rate, alongside durable royalties projected into the late 2030s and 2040s on the newer launches. Torley quantified the runway: Opdivo Qvantig only ~17% converted against a 30–40% expectation, Ocrevus at ~20% conversion of an $11 billion peak franchise, Rybrevant Faspro annualizing near $1.3 billion against a $5 billion-plus projection. That narrowing R&D spend is what funds the argument. R&D of $28M against $481M of revenue — roughly 6% of sales, even after a 58% year-over-year increase tied to HyperCon and AeroCon work. The offset is the balance sheet. Halozyme raised $1.5 billion of convertibles this quarter, ran $400 million of buybacks, and carries net leverage of 2.4x — but the filed figures are starker: effective net cash of –$2.0B, with liabilities at 94.4% of assets, up 10.6 points year over year. Against that, 12x free cash flow (less SBC) is not an expensive price for a royalty compounder. The honest read: the operating story is exceptional and accelerating, the European legal story turned from threat to asset in a single ruling, and the second platform is real but pre-clinical. What a buyer is paying for today is the gap between a judgment in The Hague and a docket in Washington — and the market has already decided which way it thinks that gap resolves.